Would a HER2 mutation on NGS of a biopsy of a breast cancer liver metastasis change your management if the met is HER2- by IHC with the initial localized disease being HER2+?  

If NGS was positive would you treat with HER2 directed therapy? Is this a different clone and should be treated as such?



Answer from: Medical Oncologist at Academic Institution

Answer from: Medical Oncologist at Community Practice

Answer from: Medical Oncologist at Community Practice
Comments
Medical Oncologist
Yet another interesting "plot twist" in the HER2 s...
Sign in or Register to read more